291 related articles for article (PubMed ID: 25168830)
1. Permeability factors in focal and segmental glomerulosclerosis.
Reiser J; Nast CC; Alachkar N
Adv Chronic Kidney Dis; 2014 Sep; 21(5):417-21. PubMed ID: 25168830
[TBL] [Abstract][Full Text] [Related]
2. Soluble urokinase receptor and focal segmental glomerulosclerosis.
Reiser J; Wei C; Tumlin J
Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):428-32. PubMed ID: 22569341
[TBL] [Abstract][Full Text] [Related]
3. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
[TBL] [Abstract][Full Text] [Related]
4. Update on Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplantation.
Shoji J; Mii A; Terasaki M; Shimizu A
Nephron; 2020; 144 Suppl 1():65-70. PubMed ID: 33260184
[TBL] [Abstract][Full Text] [Related]
5. Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
Kim EY; Roshanravan H; Dryer SE
Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2342-2354. PubMed ID: 28629718
[TBL] [Abstract][Full Text] [Related]
6. suPAR and chronic kidney disease-a podocyte story.
Zeier M; Reiser J
Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
[TBL] [Abstract][Full Text] [Related]
7. The pathogenesis of focal segmental glomerulosclerosis.
Jefferson JA; Shankland SJ
Adv Chronic Kidney Dis; 2014 Sep; 21(5):408-16. PubMed ID: 25168829
[TBL] [Abstract][Full Text] [Related]
8. Podocyte expression of nonmuscle myosin heavy chain-IIA decreases in idiopathic nephrotic syndrome, especially in focal segmental glomerulosclerosis.
Miura K; Kurihara H; Horita S; Chikamoto H; Hattori M; Harita Y; Tsurumi H; Kajiho Y; Sawada Y; Sasaki S; Igarashi T; Kunishima S; Sekine T
Nephrol Dial Transplant; 2013 Dec; 28(12):2993-3003. PubMed ID: 24042022
[TBL] [Abstract][Full Text] [Related]
9. Circulating permeability factor suPAR: from concept to discovery to clinic.
Reiser J
Trans Am Clin Climatol Assoc; 2013; 124():133-8. PubMed ID: 23874017
[TBL] [Abstract][Full Text] [Related]
10. Focal and segmental glomerulosclerosis in murine models: a histological and ultrastructural characterization with immunohistochemistry correlation of glomerular CD44 and WT1 expression.
Husain S; Ginawi I; Bashir AI; Kfoury H; Al Johani TE; Hagar H; Raddaoui L; Al Ghonaim M; Alsuwaida A
Ultrastruct Pathol; 2018; 42(5):430-439. PubMed ID: 30285525
[TBL] [Abstract][Full Text] [Related]
11. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Chen JS; Chang LC; Wu CZ; Tseng TL; Lin JA; Lin YF; Cheng CW
J Biomed Sci; 2016 Feb; 23():24. PubMed ID: 26846181
[TBL] [Abstract][Full Text] [Related]
12. Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis.
Otalora L; Chavez E; Watford D; Tueros L; Correa M; Nair V; Ruiz P; Wahl P; Eddy S; Martini S; Kretzler M; Burke GW; Fornoni A; Merscher S
PLoS One; 2019; 14(10):e0222948. PubMed ID: 31581251
[TBL] [Abstract][Full Text] [Related]
13. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
Kronbichler A; Saleem MA; Meijers B; Shin JI
J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
[TBL] [Abstract][Full Text] [Related]
14. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
[TBL] [Abstract][Full Text] [Related]
15. Podocin and uPAR are good biomarkers in cases of Focal and segmental glomerulosclerosis in pediatric renal biopsies.
Pereira LHM; da Silva CA; Monteiro MLGDR; Araújo LS; Rocha LP; Reis MBDR; Ramalho FS; Corrêa RRM; Silva MV; Reis MA; Machado JR
PLoS One; 2019; 14(6):e0217569. PubMed ID: 31188898
[TBL] [Abstract][Full Text] [Related]
16. Primary Focal Segmental Glomerulosclerosis Plasmas Increase Lipid Droplet Formation and Perilipin-2 Expression in Human Podocytes.
den Braanker DJW; Maas RJH; van Mierlo G; Parr NMJ; Bakker-van Bebber M; Deegens JKJ; Jansen PWTC; Gloerich J; Willemsen B; Dijkman HB; van Gool AJ; Wetzels JFM; Rinschen MM; Vermeulen M; Nijenhuis T; van der Vlag J
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613637
[TBL] [Abstract][Full Text] [Related]
17. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
[TBL] [Abstract][Full Text] [Related]
18. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
BMC Med; 2014 May; 12():81. PubMed ID: 24884842
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HIV-associated nephropathy.
Yang Y; Gubler MC; Beaufils H
Nephron; 2002 Jul; 91(3):416-23. PubMed ID: 12119471
[TBL] [Abstract][Full Text] [Related]
20. Partial podocyte replenishment in experimental FSGS derives from nonpodocyte sources.
Kaverina NV; Eng DG; Schneider RR; Pippin JW; Shankland SJ
Am J Physiol Renal Physiol; 2016 Jun; 310(11):F1397-413. PubMed ID: 27076646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
